Glysantis is a pre-clinical stage biotechnology company developing first-in-class nanomedicines to treat solid tumors. We have leveraged our proprietary NanoDendrix glycogen nanoparticle platform to spin out two early stage oncology programs. GLY-100 is a TLR targeting nanoparticle that induces a strong innate immune response in cancer and immune cells, with the potential to enhance standard-of-care chemotherapy and immunotherapy in hard-to-treat patient populations. GLY-200 is a nanoparticle-drug conjugate for the preferential delivery of anti-cancer agents to cancer cells. Our near-term goals are to accelerate pre-clinical development of our lead candidate GLY-100 and to bolster in-house discovery and optimization of GLY-200.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
GLY-100, a TLR targeting cancer immunotherapy for the treatment of solid tumors
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):